Vanda Pharmaceuticals' APA claims against US FDA dismissed, but Appointments Clause challenge survives
MLex Summary: A US judge has dismissed allegations the US Food and Drug Administration violated the Administrative Procedure Act when approving MSN Pharmaceuticals' bioequivalent to Vanda Pharmaceuticals' sleep disorder drug Hetlioz....To view the full article, register now.
Already a subscriber? Click here to view full article